List of Tables:
Table 1. Snapshot of North America Biosimilars Market in Balanced Perspective, 2019-2030 17
Table 2. Growth Rate of World GDP, 2020-2022 22
Table 3. World Health Spending by Region, $ bn, 2013-2020 30
Table 4. Main Product Trends and Market Opportunities in North America Biosimilars Market 34
Table 5. North America Biosimilars Market by Product Type, 2019-2030, $ mn 42
Table 6. North America Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, $ mn 45
Table 7. North America Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, $ mn 50
Table 8. North America Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, $ mn 54
Table 9. North America Biosimilars Market by Indication, 2019-2030, $ mn 58
Table 10. North America Biosimilars Market by Manufacturing, 2019-2030, $ mn 67
Table 11. North America Biosimilars Market by End User, 2019-2030, $ mn 71
Table 12. North America Biosimilars Market by Country, 2019-2030, $ mn 77
Table 13. U.S. Biosimilars Market by Product Type, 2019-2030, $ mn 82
Table 14. U.S. Biosimilars Market by Indication, 2019-2030, $ mn 82
Table 15. U.S. Biosimilars Market by End User, 2019-2030, $ mn 82
Table 16. FDA Approved Biosimilars in U.S., 2015-2020 83
Table 17. U.S. Select Pending Biosimilar BLAs as of December 2020 87
Table 18. U.S. Biosimilar Market Share (market share data through July 2020) 88
Table 19. Canada Biosimilars Market by Product Type, 2019-2030, $ mn 90
Table 20. Canada Biosimilars Market by Indication, 2019-2030, $ mn 90
Table 21. Canada Biosimilars Market by End User, 2019-2030, $ mn 90
Table 22. Mexico Biosimilars Market by Product Type, 2019-2030, $ mn 92
Table 23. Mexico Biosimilars Market by Indication, 2019-2030, $ mn 92
Table 24. Mexico Biosimilars Market by End User, 2019-2030, $ mn 92
Table 25. Breakdown of World Market by Key Vendor, 2020, % 95
Table 26. AMEGA Biotech S.A.: Company Snapshot 98
Table 27. AMEGA Biotech S.A.: Business Segmentation 98
Table 28. AMEGA Biotech S.A.: Product Portfolio 99
Table 29. AMEGA Biotech S.A.: Revenue, 2018-2020, $ mn 99
LIST OF FIGURE
List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 4. North America Biosimilars Market, 2019-2030, $ mn 18
Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 19
Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 19
Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 20
Figure 8. Impact of COVID-19 on Business 24
Figure 9. Primary Drivers and Impact Factors of North America Biosimilars Market 26
Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 29
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 29
Figure 12. Primary Restraints and Impact Factors of North America Biosimilars Market 31
Figure 13. Investment Opportunity Analysis 35
Figure 14. Porters Fiver Forces Analysis of North America Biosimilars Market 38
Figure 15. Breakdown of North America Biosimilars Market by Product Type, 2019-2030, % of Revenue 43
Figure 16. North America Addressable Market Cap in 2021-2030 by Product Type, Value ($ mn) and Share (%) 43
Figure 17. North America Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, $ mn 44
Figure 18. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, $ mn 46
Figure 19. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, $ mn 47
Figure 20. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, $ mn 48
Figure 21. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, $ mn 49
Figure 22. North America Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, $ mn 50
Figure 23. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, $ mn 51
Figure 24. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, $ mn 52
Figure 25. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, $ mn 53
Figure 26. North America Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, $ mn 54
Figure 27. North America Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, $ mn 55
Figure 28. North America Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, $ mn 56
Figure 29. North America Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, $ mn 57
Figure 30. Breakdown of North America Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 59
Figure 31. North America Addressable Market Cap in 2021-2030 by Indication, Value ($ mn) and Share (%) 59
Figure 32. North America Biosimilars Market by Indication: Cancer, 2019-2030, $ mn 60
Figure 33. North America Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, $ mn 61
Figure 34. North America Biosimilars Market by Indication: Blood Disorder, 2019-2030, $ mn 62
Figure 35. North America Biosimilars Market by Indication: Diabetes, 2019-2030, $ mn 63
Figure 36. North America Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, $ mn 64
Figure 37. North America Biosimilars Market by Indication: Infectious Diseases, 2019-2030, $ mn 65
Figure 38. North America Biosimilars Market by Indication: Other Indications, 2019-2030, $ mn 66
Figure 39. Breakdown of North America Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 68
Figure 40. North America Addressable Market Cap in 2021-2030 by Manufacturing, Value ($ mn) and Share (%) 68
Figure 41. North America Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, $ mn 69
Figure 42. North America Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, $ mn 70
Figure 43. Breakdown of North America Biosimilars Market by End User, 2019-2030, % of Revenue 72
Figure 44. North America Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%) 72
Figure 45. North America Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, $ mn 73
Figure 46. North America Biosimilars Market by End User: Research Institutes, 2019-2030, $ mn 74
Figure 47. North America Biosimilars Market by End User: Other End Users, 2019-2030, $ mn 75
Figure 48. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue 77
Figure 49. Contribution to North America 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 78
Figure 50. U.S. Biosimilars Market, 2019-2030, $ mn 80
Figure 51. Biosimilar Approvals and Launches in U.S., 2015-2020 80
Figure 52. Canada Biosimilars Market, 2019-2030, $ mn 89
Figure 53. Biosimilars Market in Mexico, 2019-2030, $ mn 91
Figure 54. Growth Stage of North America Biosimilars Industry over the Forecast Period 93
